Your browser doesn't support javascript.
loading
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
Baqar, Shahida; Bonavia, Aurelio; Louis Bourgeois, A; Campo, Joseph J; Clifford, Allison; Hanevik, Kurt; Hasso-Agopsowicz, Mateusz; Hausdorff, William; Kaminski, Robert; MacLennan, Calman A; Mantis, Nicholas; Martin, Laura B; Omore, Richard; Pasetti, Marcela; Pavlinac, Patricia; Phalipon, Armelle; Poly, Frédéric; Porter, Chad; Ramasamy, Maheshi N; Rogawski McQuade, Elizabeth T; Sztein, Marcelo B; Walker, Richard.
Afiliação
  • Baqar S; US National Institutes of Health, United States.
  • Bonavia A; Bill & Melinda Gates Medical Research Institute, United States.
  • Louis Bourgeois A; PATH, United States.
  • Campo JJ; Antigen Discovery, Inc, United States.
  • Clifford A; PATH, United States. Electronic address: aclifford@path.org.
  • Hanevik K; University of Bergen, Norway; Norwegian National Advisory Unit for Tropical Infectious Diseases, Medical Department, Haukeland University Hospital, Norway.
  • Hasso-Agopsowicz M; World Health Organization, Switzerland.
  • Hausdorff W; PATH, United States; Faculty of Medicine, Université Libre de Bruxelles, Belgium.
  • Kaminski R; Latham BioPharm Group, United States.
  • MacLennan CA; Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation, United Kingdom; The Jenner Institute, United Kingdom.
  • Mantis N; Wadsworth Center, New York State Department of Health, United States.
  • Martin LB; US Pharmacopeial Convention, United States.
  • Omore R; Kenya Medical Research Institute Center for Global Health Research, Kenya.
  • Pasetti M; University of Maryland, United States.
  • Pavlinac P; University of Washington, United States.
  • Phalipon A; Institut Pasteur, France.
  • Poly F; Naval Medical Research Command, United States.
  • Porter C; Naval Medical Research Command, United States.
  • Ramasamy MN; Oxford Vaccine Group, University of Oxford, United Kingdom.
  • Rogawski McQuade ET; Emory University, United States.
  • Sztein MB; University of Maryland, United States.
  • Walker R; PATH, United States.
Vaccine ; 42(7): 1445-1453, 2024 Mar 07.
Article em En | MEDLINE | ID: mdl-38036392
ABSTRACT
The global public health nonprofit organization PATH hosted the third Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Washington, DC, from November 29 to December 1, 2022. This international gathering focused on cutting-edge research related to the development of vaccines against neglected diarrheal pathogens including Shigella, enterotoxigenic Escherichia coli (ETEC), Campylobacter, and non-typhoidal Salmonella. In addition to the conference's plenary content, the agenda featured ten breakout workshops on topics of importance to the enteric vaccine field. This unique aspect of VASE Conferences allows focused groups of attendees to engage in in-depth discussions on subjects of interest to the enteric vaccine development community. In 2022, the workshops covered a range of topics. Two focused on the public health value of enteric vaccines, with one examining how to translate evidence into policy and the other on the value proposition of potential combination vaccines against bacterial enteric pathogens. Two more workshops explored new tools for the development and evaluation of vaccines, with the first on integrating antigen/antibody technologies for mucosal vaccine and immunoprophylactic development, and the second on adjuvants specifically for Shigella vaccines for children in low- and middle-income countries. Another pair of workshops covered the status of vaccines against two emerging enteric pathogens, Campylobacter and invasive non-typhoidal Salmonella. The remaining four workshops examined the assessment of vaccine impact on acute and long-term morbidity. These included discussions on the nature and severity of intestinal inflammation; cellular immunity and immunological memory in ETEC and Shigella infections; clinical and microbiologic endpoints for Shigella vaccine efficacy studies in children; and intricacies of protective immunity to enteric pathogens. This article provides a brief summary of the presentations and discussions at each workshop in order to share these sessions with the broader enteric vaccine field.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Shigella / Vacinas contra Escherichia coli / Vacinas contra Shigella / Infecções por Escherichia coli / Escherichia coli Enterotoxigênica Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Shigella / Vacinas contra Escherichia coli / Vacinas contra Shigella / Infecções por Escherichia coli / Escherichia coli Enterotoxigênica Limite: Child / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article